8.17, 8.18 - GM organisms, medicines and decisions

From a gene to a protein medicine

A genetically modified host can use an introduced gene to make a protein that would otherwise be absent or produced differently.

For a recombinant protein medicine, selected coding DNA is combined with other DNA needed for expression in a host. The host may be a microorganism, a plant or an animal. The introduced sequence may be carried on a DNA molecule such as a bacterial plasmid or incorporated into a cell's genome. Merely having the DNA is insufficient: appropriate control sequences must allow the gene to be expressed in the relevant cells.

The central biological chain is the same in each host. The coding DNA is transcribed into RNA, and ribosomes translate the mRNA into a polypeptide. The genetic code is nearly universal, so a host can read coding information originating from another species. However, the finished protein must also have a suitable shape and any necessary processing to work. These requirements help determine the choice of host.

For example, a human genomic gene may contain introns. Bacteria do not carry out the human RNA-splicing process, so bacterial production uses a suitable intron-free coding sequence rather than assuming that an unaltered human genomic gene will work.

The resulting cells are maintained as a production source. Growing more producing cells, or breeding a suitable producing organism, can provide repeated supplies. Depending on the host and protein, the product may remain inside cells or be secreted into a fluid such as a culture medium, milk or egg white. It must then be recovered and purified from the other material. Purification separates the desired protein from unwanted host proteins, cell material and other contaminants.

Finally, tests check properties such as identity, purity, concentration and biological activity before suitable batches are released. A correct DNA sequence does not demonstrate correct folding, an uncontaminated product or an effective treatment. Manufacturing controls and appropriate evidence about use in patients answer different questions.

Microorganisms as medicine producers

Microorganisms can provide a large population of producing cells in a contained production vessel.

Bacteria reproduce rapidly under suitable controlled conditions, so a producing cell population can be expanded without repeatedly obtaining protein from human donors or animal organs. Closed vessels also allow the production environment to be controlled. These are potential advantages, rather than a guarantee that every microbial medicine will be cheap or easy to make: recovery, purification, testing and distribution still have costs.

Human insulin is a peptide hormone used in diabetes treatment. The current US label for Humulin R identifies a non-pathogenic laboratory strain of Escherichia coli as its recombinant production host. The cells express the introduced coding information; the material produced is processed as necessary to obtain the active insulin product, then purified and formulated at a controlled concentration. The medicine supplies insulin protein, rather than living production bacteria. Humulin R label, description.

Host choice matters because expression and protein finishing are different steps. Some therapeutic proteins need particular attached carbohydrate groups, a modification called glycosylation, to function or persist appropriately in the body. Standard E. coli production does not provide the same glycosylation machinery as human cells. A bacterial product with the required amino acid sequence is therefore not automatically suitable for every therapeutic purpose. Insulin does not require this carbohydrate attachment, which helps make bacterial production appropriate for it.

Microorganisms also include eukaryotes such as yeast. Yeast can perform some processing that bacteria cannot, but its modifications are not automatically identical to those of humans. The required product must be tested, rather than choosing “microorganism” as though all hosts have the same capabilities.

Plants and animals as medicine producers

Plant and animal cells can also express introduced coding DNA, and some can make useful complex protein products.

A plant production system can use whole plants or cultured plant cells. In a whole plant, the protein may accumulate in a selected tissue, which is harvested for recovery and purification. A cultured-cell system instead maintains producing plant cells in contained vessels. It need not produce flowering plants or pollen. Both use plant cells' gene-expression machinery; neither makes eating an ordinary plant equivalent to receiving a controlled medicine.

Taliglucerase alfa, the active protein in Elelyso, is an enzyme replacement treatment for type 1 Gaucher disease. Its US label describes recombinant production in carrot cell culture. The enzyme is obtained from the production system and purified for administration as a medicine. This is a real plant-cell example, rather than a claim that patients should eat GM carrots. Elelyso label, description and indications.

In an animal production system, the introduced gene can be expressed in particular tissues, allowing a useful protein to be secreted into a collectable material. For example, genetically modified chickens produce sebelipase alfa in egg white. This is the active enzyme in Kanuma, used for lysosomal acid lipase deficiency. Egg white provides starting material from which the protein is purified; the final medicine is not an egg preparation intended as food. Kanuma label, description and indications.

The following comparison brings the three host groups together. These examples appear in US medicine labels checked in October 2026; authorisation and availability can differ between countries. They are different proteins for different conditions, so this table cannot rank their clinical effectiveness or prices.

Plant and animal cells can attach carbohydrate groups, but these modifications need not exactly match one another or human modifications. Their suitability is a property of the particular product and production system. There is no rule that an animal host is always better than a plant or microbial host.

Benefits and product control

Producing a useful protein creates a potential benefit, but the quality of the released medicine determines whether that benefit can be delivered reliably.

GM production can provide a continuing supply of a human protein without relying on extraction from a limited supply of donor tissues. It can also reduce dependence on animal organs used as extraction sources. A suitable host can make protein with the required biological action, and production can be scaled to meet demand. These benefits matter when a missing or deficient protein causes disease. Enzyme replacement can compensate for a missing activity without correcting the patient's underlying gene: production of a recombinant medicine is distinct from gene therapy.

Controlled manufacturing can support consistent concentration and activity between released batches. However, a large amount of expressed protein is not necessarily a large amount of usable medicine. Incorrect folding, unsuitable processing or contamination can require a batch to be rejected. Purification and quality checks help prevent such material from reaching patients. Avoiding donor tissue removes some source-related concerns, but it does not establish freedom from every contaminant or every adverse reaction.